Contact Us
Drug Search Results
More Filters [+]

Ruboxistaurin

Alternative Names: ruboxistaurin, ly333531
Latest Update: 2024-02-06
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: PKC Beta Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Chromaderm
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ruboxistaurin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Type 2 Diabetes|Peripheral Nervous System Diseases|Type 1 Diabetes|Macular Edema|Diabetic Retinopathy

Phase 2: Other|Diabetic Nephropathy|Heart Failure|Macular Edema|Diabetic Retinopathy|Type 2 Diabetes|Oxidative Stress

Phase 1: Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCT02769611

P2

Withdrawn

Heart Failure

2022-01-01

2005-000900-15

P2

Completed

Diabetic Retinopathy|Macular Edema

2011-07-14

B7A-MC-MBCU

P3

Completed

Macular Edema

2011-07-01

B7A-MC-MBDL

P3

Completed

Macular Edema|Diabetic Retinopathy

2010-04-01

Recent News Events

Date

Type

Title

02/06/2024

PubMed

 Role of Protein Kinase C in Metabolic Regulation of Coronary Endothelial Small Conductance Calcium-Activated Potassium Channels.

02/01/2024

PubMed

 Empagliflozin prevents oxidative stress in human coronary artery endothelial cells via the NHE/PKC/NOX axis.

07/06/2023

PubMed

 Acute protein kinase C beta inhibition preserves coronary endothelial function after cardioplegic hypoxia/reoxygenation.

12/21/2021

News Article

 DermBiont Raises $28 Million and Acquires Chromaderm to Expand Targeted Topical Therapeutics in Development

06/11/2020

News Article

 Diabetes and Peripheral Artery Disease

06/11/2020

News Article

 Diabetes and Peripheral Artery Disease

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions